| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/19/2011 | CA2459165C Dosage forms having prolonged active ingredient release |
| 07/19/2011 | CA2452239C Pharmaceutical formulation having a masked taste and method for the production thereof |
| 07/19/2011 | CA2434314C Method to enhance the immunogenicity of an antigen |
| 07/19/2011 | CA2431606C Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 07/19/2011 | CA2417388C Therapeutic polyanhydride compounds for drug delivery |
| 07/19/2011 | CA2220555C Methods and compositions for healing and repair of connective tissue attachment |
| 07/14/2011 | WO2011085393A1 Stable insulin formulations and methods of making and using thereof |
| 07/14/2011 | WO2011085301A1 Biomatrices to attract and retain regenerative and reparative cells |
| 07/14/2011 | WO2011085298A2 Compositions comprising pigment particles entrapped in collapsed polymeric microspheres, and methods of making the same |
| 07/14/2011 | WO2011085209A2 Methods and compositions for applying moxifloxacin to the ear |
| 07/14/2011 | WO2011085013A2 Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same |
| 07/14/2011 | WO2011084925A2 Biomaterials made from human hair |
| 07/14/2011 | WO2011084750A1 Antibody formulation |
| 07/14/2011 | WO2011084620A2 Particles for multiple agent delivery |
| 07/14/2011 | WO2011084610A1 Liposomes for preventing the spread of hiv |
| 07/14/2011 | WO2011084518A2 Therapeutic polymeric nanoparticles comprising corticosteroids and methods of making and using same |
| 07/14/2011 | WO2011084513A2 Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| 07/14/2011 | WO2011084458A2 Polymer-based compositions and methods for treatment of peritoneal disorders |
| 07/14/2011 | WO2011083845A1 Targeting agent for tumor site |
| 07/14/2011 | WO2011083787A1 Anti-inflammatory analgesic adhesive patch for external use |
| 07/14/2011 | WO2011059931A3 Nanosuspension of a poorly soluble drug made by microfluidization process |
| 07/14/2011 | WO2011045682A3 Active agent containing polymer network delivery composition and articles using the same |
| 07/14/2011 | WO2011045681A3 Carbohydrate entrapped active agent delivery composition and articles using the same |
| 07/14/2011 | WO2011041470A3 Sustained-release opiate and opiate derivative compositions |
| 07/14/2011 | WO2011036676A3 Stable cocrystals of temozolomide |
| 07/14/2011 | WO2011034323A3 Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system |
| 07/14/2011 | WO2011028485A3 Tumoricidal, bactericidal, or viricidal macrophage activation |
| 07/14/2011 | WO2011028016A3 Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers |
| 07/14/2011 | WO2011026076A3 Topical formulations comprising a steroid |
| 07/14/2011 | WO2011026003A3 A xylitol containing comestible product |
| 07/14/2011 | WO2011021804A3 Sensitive polymer capsule and method for preparing same |
| 07/14/2011 | WO2011020933A3 Liposomes covered with the extracellular domain of the apo2l/trail protein |
| 07/14/2011 | WO2011018541A3 Hydrogels based on poloxamers with a star structure for the controlled release of active substances |
| 07/14/2011 | WO2010111221A3 Compositions and methods for preferential distribution of active agents to injury sites |
| 07/14/2011 | US20110172724 Biocompatible magnesium material |
| 07/14/2011 | US20110172390 Protein-Proteophore Complexes |
| 07/14/2011 | US20110172314 Amphiphilic branched polymers and their use as emulsifiers |
| 07/14/2011 | US20110172196 Pharmaceutical composition and method for treating hypogonadism |
| 07/14/2011 | US20110172166 Anionic polysaccharides functionalized by a hydrophobic acid derivative |
| 07/14/2011 | US20110172161 Composition for therapeutic and cosmetic botulinum toxin |
| 07/14/2011 | US20110172141 Process for preparing microparticles |
| 07/14/2011 | US20110172139 Peptides whose uptake by cells is controllable |
| 07/14/2011 | US20110171309 Compositions and Methods for Composite Nanoparticle Hydrogels |
| 07/14/2011 | US20110171283 Composition containing at least one nutrivite, at least one disinfecting or decontaminating, and/or at least one protease-inhibiting active compound and/or active compound complex |
| 07/14/2011 | US20110171281 Soft capsule composition and method of use |
| 07/14/2011 | US20110171255 Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant |
| 07/14/2011 | US20110171239 pH INDUCED SILK GELS AND USES THEREOF |
| 07/14/2011 | US20110171188 Non-thermal plasma for wound treatment and associated apparatus and method |
| 07/14/2011 | US20110171166 Polymer conjugates of osteocalcin peptides |
| 07/14/2011 | US20110171165 Polymer conjugates of opioid growth factor peptides |
| 07/14/2011 | US20110171164 Polymer conjugates of glp-2-like peptides |
| 07/14/2011 | US20110171163 Polymer conjugates of ziconotide peptides |
| 07/14/2011 | US20110171162 Polymer conjugates of thymosin alpha 1 peptides |
| 07/14/2011 | US20110171160 Polymer conjugates of kiss1 peptides |
| 07/14/2011 | US20110171140 Absorption of therapeutic agents across mucosal membranes or the skin |
| 07/14/2011 | US20110171127 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer |
| 07/14/2011 | CA2804034A1 Prodrugs of heteraromatic compounds |
| 07/14/2011 | CA2786527A1 Biomatrices to attract and retain regenerative and reparative cells |
| 07/14/2011 | CA2786525A1 Methods and compositions for applying moxifloxacin to the ear |
| 07/14/2011 | CA2786400A1 Biomaterials made from human hair |
| 07/14/2011 | CA2786233A1 Anti-inflammatory analgesic adhesive patch for external use |
| 07/14/2011 | CA2785920A1 Solid oral dosage form containing olmesartan medoxomil |
| 07/14/2011 | CA2785834A1 Fatty acid derivatives and analogs of drugs |
| 07/14/2011 | CA2785754A1 Compositions comprising pigment particles entrapped in collapsed polymeric microspheres, and methods of making the same |
| 07/14/2011 | CA2784772A1 Mesalamine suppository |
| 07/14/2011 | CA2784704A1 Temperature-dependent activation of catalytic nucleic acids for controlled active substance release |
| 07/14/2011 | CA2783846A1 Antibody formulation |
| 07/13/2011 | EP2343342A1 Strong reversible hydrogels |
| 07/13/2011 | EP2343317A1 Apolipoprotein analogues |
| 07/13/2011 | EP2343316A1 Ligand binding site of RAGE and uses thereof |
| 07/13/2011 | EP2343314A2 Calcium fluoride phosphopeptide complexes |
| 07/13/2011 | EP2343089A1 Utilization of xylitol or its derivatives for taste-masking chemotherapy drugs of the quinolone-o-naphthyridone carboxylic acid group administrated in food intended for pigs |
| 07/13/2011 | EP2343080A1 PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN |
| 07/13/2011 | EP2343078A1 Light-stabilized pharmaceutical composition |
| 07/13/2011 | EP2343077A1 Derivatives of totally N-desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 07/13/2011 | EP2343076A1 Pharmaceutical composition for oral administration |
| 07/13/2011 | EP2343060A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/13/2011 | EP2343059A1 Oral preparation |
| 07/13/2011 | EP2343051A2 Anti-cancer formulation |
| 07/13/2011 | EP2343048A2 Stabilized and preserved ketotifen ophthalmic compositions |
| 07/13/2011 | EP2343045A2 Transmucosal drug delivery system |
| 07/13/2011 | EP2343044A1 Cosmetic composition for sensitive skins |
| 07/13/2011 | EP2342283A1 A functionalized cyanine having a silane linker arm, a method of preparing thereof and uses thereof |
| 07/13/2011 | EP2341942A1 Polymer conjugates of therapeutic peptides |
| 07/13/2011 | EP2341941A2 Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| 07/13/2011 | EP2341940A1 The stabilisation of proteins |
| 07/13/2011 | EP2341939A2 Dendritic cell modulatory molecule |
| 07/13/2011 | EP2341901A1 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion |
| 07/13/2011 | EP2341898A2 Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
| 07/13/2011 | EP2341897A2 Nanoparticles for immunotherapy |
| 07/13/2011 | EP2341894A2 Pharmaceutical composition |
| 07/13/2011 | EP2146750B1 Stabilized suspension |
| 07/13/2011 | EP2143438B1 Compositions and methods for the diagnosis and treatment of tumors |
| 07/13/2011 | EP1937310B8 Use of conjugates of doxorubicin with lactosaminated albumin |
| 07/13/2011 | EP1667655B1 New use, pharmaceutical preparations as well as a process for their production |
| 07/13/2011 | EP1633784B1 Ovr110 antibody compositions and methods of use |
| 07/13/2011 | EP1545553B1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 07/13/2011 | EP1181001B1 Sunscreen composition containing sol-gel microcapsules |
| 07/13/2011 | EP0872447B1 Silicon oxide powder and process for the production thereof, cosmetics made by using the same, micelle-retaining powder, and perfume-retaining powder |
| 07/13/2011 | CN1903176B Dry suspensoid of Repirinast and its prepn. method |